Objectives 6/14/2016. Cardiorenal Syndrome: Critical Link Between Heart and Kidney
|
|
- Alexina Stokes
- 6 years ago
- Views:
Transcription
1 Cardiorenal Syndrome: Critical Link Between Heart and Kidney Chris M. Bell, ACNP Cardiology Associates of North Mississippi Objectives Review the 5 Subtypes of the Cardiorenal Syndrome (CRS) Discuss the epidemiology and discriminating features of the CRS Assist in helping to understand the complexity of physiological, biochemical and neurohormonal derangements that complicate patient care Discuss treatment considerations in clinical management 1
2 Enrolled Discharges (%) 6/14/2016 Heart Failure Hits Home ACC/AHA Guidelines: Management of Fluid Status Patients should not be discharged from the hospital until a stable and effective diuretic regimen is established, and ideally, not until euvolemia is achieved Patients who are sent home before these goals are reached are at high risk of recurrence of fluid retention and early readmission because unresolved edema may itself attenuate the response to diuretics 2009 Focused Update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: J Am Coll Cardiol. 2009;53(15): doi: /j.jacc The dilemma we know what needs to be achieved but we have not been able to accomplish the desired outcome with any consistency or sustainability in many acutely decompensated heart failure patients Inadequate Diuresis During ADHF Treatment (Adhere Registry) Note: For the chart, n represents the number of patients who have both baseline and discharge weight, and the percentage is calculated based on the total patients in the corresponding population. Patients without baseline or discharge weight are omitted from the histogram calculations. ADHERE Database 7% 6% 13% 24% 30% 15% Change in Weight (lb) Change in Weight From Admission to Discharge TheNation =26,757, 68% 3% 2% (<-20) (-20 to -15) (-15 to -10) (-10 to -5) (-5 to 0) (0 to 5) (5 to 10) (>10) 2
3 Renal Disease Affects Readmissions and Mortality Majority (71%) of CHF patients with SCr >2.5 mg/dl (10% of CHF patients) will be readmitted within 6 months 1 Concurrent renal disease, seen in 6.5% of acute CHF patients in a Canadian study, is a significant independent predictor of 30-day and 1-year mortality 2 1. Krumholz et al. Am Heart J. 2000;139: Jong et al. Arch Intern Med. 2002;162:1689. Impact of Renal Function on Survival in HF Ibopamine Trial n=1906 Hillege et al. Circ. 2000; 102: Definitions Cardiorenal Syndrome (CRS) A condition in which there is dysfunction of both the cardiac and renal function Seen in heart failure patients who have renal dysfunction Seen in renal patients that develop cardiac dysfunction Risk Factors that increase chances for both HTN, Diabetes, Atherosclerosis 3
4 Schematic Overload Schematic Overload with more Arrows CRS Classifications Type 1 CRS reflects an abrupt worsening of cardiac function (e.g. acute cardiogenic shock or decompensated congestive heart failure) leading to acute kidney injury. Type 2 CRS describes chronic abnormalities in cardiac function (e.g. chronic congestive heart failure) causing progressive and permanent chronic kidney disease. Type 3 CRS consists in an abrupt worsening of renal function (e.g. acute kidney ischemia or glomerulonephritis) causing acute cardiac disorder (e.g. heart failure, arrhythmia, ischemia). Type 4 CRS describes a state of chronic kidney disease (e.g. chronic glomerular disease) contributing to decreased cardiac function, cardiac hypertrophy and/ or increased risk of adverse cardiovascular events. Type 5 CRS reflects a systemic condition (e.g. diabetes mellitus, sepsis) causing both cardiac and renal dysfunction. Ronco C. Cardiorenal syndromes: definition and classification. Contrib Nephrol. 2010;164: Epub 2010 Apr 20 4
5 Type 1 CRS reflects an abrupt worsening of cardiac function (e.g. acute cardiogenic shock or decompensated congestive heart failure) leading to acute kidney injury. Type 2 CRS describes chronic abnormalities in cardiac function (e.g. chronic congestive heart failure) causing progressive and permanent chronic kidney disease. Type 3 CRS consists in an abrupt worsening of renal function (e.g. acute kidney ischemia or glomerulonephritis) causing acute cardiac disorder (e.g. heart failure, arrhythmia, ischemia). Type 4 CRS describes a state of chronic kidney disease (e.g. chronic glomerular disease) contributing to decreased cardiac function, cardiac hypertrophy and/ or increased risk of adverse cardiovascular events. Type 5 CRS reflects a systemic condition (e.g. diabetes mellitus, sepsis) causing both cardiac and renal dysfunction. CRS Type I Key concepts Acute Generally, four broad subsets of heart failure 1 Acutely decompensated failure Hypertensive failure with preserved EF and pulmonary edema Cardiogenic shock Right ventricular failure Consider pre-existing risk factors, such as 2,3 Underlying renal insufficiency Worsening heart failure class Tachyarrhythmias Hypo/Hypertension High dose diuretic therapy Primary clinical observation is inadequate renal perfusion leading to low cardiac output with marked elevation of venous pressures resulting in renal congestion 1. Nohria A, et al. J Am Coll Cardiol. 2008;51(13): Forman DE, et al. J Am Coll Cardiol. 2004;43(1): Cowie MR, Eur Heart J. 2006;27(10): CRS Type I Treatment Considerations Decongestion if paramount If this is a relatively new condition the traditional approaches are often successful 1 Diuretics Vasodilators And, in the case of cardiogenic shock -- pressors If acute on chronic, then it is often more difficult due to refractory treatment responsiveness 2 1. Dickstein K, et al Europace. 2010;12(11): Pasquale Congest Heart Fail. 2007;13(2):
6 CRS Type 1 Treatment Considerations cont. Diuretics Loop diuretic preferred and intravenously Bolus vs Continuous Dose Trial 1 Augmented with low dose Dopamine DAD-HF 2 Ultrafiltration To Be or Not to Be 3,4,5 UNLOAD, CARRESS, AVOID-HF Up in the Air Consider plasma refill rate/hemoconcentration 6 1. Felker GM. New England Journal of Medicine. 2011;364(9): Giamouzis G, J Card Fail. 2010;16(12): Costanzo MR, J Am Coll Cardiol. 2007;49(6): Bart BA, New England Journal of Medicine. 2012;367(24): New England Journal of Medicine. 2013;368(12): Testani JM, Circulation. 2010;122(3): CRS Type 1 Treatment Considerations cont. Vasodilators Nitroglycerin and nitropreside Limited data and cautious recommendations 1,2 Nesiritide Initially looked good but fell out of favor 3 1. Mullens W, 2008;52(3): Yancy CW, et al ACCF/AHA guideline J Am Coll Cardiol. 2013;62(16):e Chen HH, Circ Heart Fail. 2013;6(5): CRS Type 1 Treatment Considerations cont. Inotropes/pressors More symptomatic relief, palliative measures, or bridge to decision overall associated with high morbidity and mortality, especially arrhythmogenic death 1 More novel agents 2,3 Vasopressin Levosimendan Relaxin 1. Yancy CW, et al ACCF/AHA guideline J Am Coll Cardiol. 2013;62(16):e Konstam MA, Jama. 2007;297(12): Triposkiadis F, Expert Opin Investig Drugs. 2009;18(6):
7 Type 1 CRS reflects an abrupt worsening of cardiac function (e.g. acute cardiogenic shock or decompensated congestive heart failure) leading to acute kidney injury. Type 2 CRS describes chronic abnormalities in cardiac function (e.g. chronic congestive heart failure) causing progressive and permanent chronic kidney disease. Type 3 CRS consists in an abrupt worsening of renal function (e.g. acute kidney ischemia or glomerulonephritis) causing acute cardiac disorder (e.g. heart failure, arrhythmia, ischemia). Type 4 CRS describes a state of chronic kidney disease (e.g. chronic glomerular disease) contributing to decreased cardiac function, cardiac hypertrophy and/ or increased risk of adverse cardiovascular events. Type 5 CRS reflects a systemic condition (e.g. diabetes mellitus, sepsis) causing both cardiac and renal dysfunction. CRS Type 2 Key Concepts Chronic abnormalities Cardiac is Primary (Type 2 and Type 4 are often very difficult to distinguish) Make an effort to discern which is primary cardiac vs renal Very few chronic heart failure patients present without some degree of renal dysfunction (ADHERE); furthermore, this co-existent relationship is associate with poor out comes Heywood JT, J Card Fail. 2007;13(6): CRS Type 2 Treatment Considerations Primary goal is evidence based care of the patient Aggressively prudent up-titration of ACE/ARB Hypotension, NSAIDS Carvedilol may have a more favorable effect on renal function 1 Spironolactone should be considered with attention to hyperkalemia How does PARADIGM fit into the CRS paradigm Possibly more favorable renal effects 2 Diuretics and diuretic resistance 1. Bakris GL, Kidney Int. 2006;70(11): Solomon SD, Lancet. 2012;380(9851):
8 Elevated Neurohormone Levels Cause Diuretic Resistance Glomerulus Norepinephrine (and endothelin) decreases renal blood flow and GFR Proximal Tubule Angiotensin II increases sodium reabsorption Collecting Duct Aldosterone increases sodium reabsorption Krämer et al. Am J Med. 1999;106:90. 8
9 UNaV, meq/6 h 6/14/2016 CRS Type 2 Treatment Considerations cont Diuretic Resistence 1 Short-term (braking phenomena) Poorly understood Long-term distal nephron hypertrophy May be benefited by combination therapy 1. Brater DC. Diuretic therapy. N Engl J Med. 1998;339(6): Short-Term (Braking Phenomena) Na + Excretion Net Diuresis After 4 Days of Rx = 0 ml Na + Intake Before F F1 F2 F3 F4 F = Furosemide Time, Days 1. Wilcox et al. Kidney Int. 1987;31:135. Na + Reaccumulation Between Furosemide Doses Long Term tolerance Tubular hypertrophy to compensate for salt loss Brater. N Engl J Med. 1998;339:387. 9
10 FENa,% 6/14/2016 Result of diuretic tolerance Fractional Na Excretion Normal CRF CHF Secretory Defect [Furosemide], µg/ml Ellison. Cardiology. 2001;96: Decreased Maximal Response Type 1 CRS reflects an abrupt worsening of cardiac function (e.g. acute cardiogenic shock or decompensated congestive heart failure) leading to acute kidney injury. Type 2 CRS describes chronic abnormalities in cardiac function (e.g. chronic congestive heart failure) causing progressive and permanent chronic kidney disease. Type 3 CRS consists in an abrupt worsening of renal function (e.g. acute kidney ischemia or glomerulonephritis) causing acute cardiac disorder (e.g. heart failure, arrhythmia, ischemia). Type 4 CRS describes a state of chronic kidney disease (e.g. chronic glomerular disease) contributing to decreased cardiac function, cardiac hypertrophy and/ or increased risk of adverse cardiovascular events. Type 5 CRS reflects a systemic condition (e.g. diabetes mellitus, sepsis) causing both cardiac and renal dysfunction. 10
11 CRS Type 3 Key Concepts Acute Kidney Injury Contrast induced kidney injury Drug-induced nephropathies Kidney injury post major surgery Rhabdomyloysis Post-infectious glomerulonephritis CRS Type 3 Treatment Considerations Avoid the insult Assess for vulnerable patient populations Hydrate Novel therapies Avert System Technology (AVERT clinical trial (NCT ) Type 1 CRS reflects an abrupt worsening of cardiac function (e.g. acute cardiogenic shock or decompensated congestive heart failure) leading to acute kidney injury. Type 2 CRS describes chronic abnormalities in cardiac function (e.g. chronic congestive heart failure) causing progressive and permanent chronic kidney disease. Type 3 CRS consists in an abrupt worsening of renal function (e.g. acute kidney ischemia or glomerulonephritis) causing acute cardiac disorder (e.g. heart failure, arrhythmia, ischemia). Type 4 CRS describes a state of chronic kidney disease (e.g. chronic glomerular disease) contributing to decreased cardiac function, cardiac hypertrophy and/ or increased risk of adverse cardiovascular events. Type 5 CRS reflects a systemic condition (e.g. diabetes mellitus, sepsis) causing both cardiac and renal dysfunction. 11
12 CRS Type 4 Key Concepts Chronic abnormalities Renal vs Primary (Type 2 and Type 4 are often very difficult to distinguish) Principle concept is clinical management aimed at slowing the progression of renal dysfunction CRS Type 4 Treatment Considerations Appreciate the degree of renal insufficiency when considering medications and dosage, i.e. digoxin Be mindful of over diuresis Consider the possibility of chronic anemia No benefit in RED-HF(epo) 1 Interesting benefits of FAIR-HF (iron) 2 1. Swedberg K, N Engl J Med. 2013;368(13): Anker SD, N Engl J Med. 2009;361(25): Type 1 CRS reflects an abrupt worsening of cardiac function (e.g. acute cardiogenic shock or decompensated congestive heart failure) leading to acute kidney injury. Type 2 CRS describes chronic abnormalities in cardiac function (e.g. chronic congestive heart failure) causing progressive and permanent chronic kidney disease. Type 3 CRS consists in an abrupt worsening of renal function (e.g. acute kidney ischemia or glomerulonephritis) causing acute cardiac disorder (e.g. heart failure, arrhythmia, ischemia). Type 4 CRS describes a state of chronic kidney disease (e.g. chronic glomerular disease) contributing to decreased cardiac function, cardiac hypertrophy and/ or increased risk of adverse cardiovascular events. Type 5 CRS reflects a systemic condition (e.g. diabetes mellitus, sepsis) causing both cardiac and renal dysfunction. 12
13 CRS Type 5 Key Concepts Essentially, a simultaneous acute/chronic dysfunction of both the cardio and renal systems Limited studies and least understood; however, as more organs fail outcomes are obviously worse CRS Type 5 Treatment Considerations Prompt identification and treatment of the offending source Hydration Conservative vs Liberal 1 Pressor consideration Norepinephrine and vasopressor dopamine are both associated with high mortality but norepinephrine may have less adverse events 2 1. Wiedemann HP, N Engl J Med. 2006;354(24): De Backer D, N Engl J Med. 2010;362(9): CRS Complicated Cardio-Renal Syndrome is very real and very complicated It is a marker for Advanced Management It is a tremendous burden leading to readmissions and death Effective treatment must be unique to the patient 13
14 14
Pivotal Role of Renal Function in Acute Heart failure
Pivotal Role of Renal Function in Acute Heart failure Doron Aronson MD, FESC Department of Cardiology RAMBAM Health Care Campus Haifa, Israel Classification and definitions of cardiorenal syndromes CRS
More informationThe Cardiorenal Syndrome in Heart Failure
The Cardiorenal Syndrome in Heart Failure Van N Selby, MD Assistant Professor of Medicine Advanced Heart Failure Program, UCSF October 9, 2015 Disclosures None 1 Cardiorenal Syndrome (CRS) A pathophysiologic
More informationHeart Failure and Renal Disease Cardiorenal Syndrome
Advanced Heart Failure: Clinical Challenges Heart Failure and Renal Disease Cardiorenal Syndrome 17 th Apr 2015 Ju-Hee Lee, M.D Cardiovascular Center, Chungbuk National University Hospital Chungbuk National
More informationHeart Failure and Renal Failure. Gerasimos Filippatos, MD, FESC, FHFA President HFA
Heart Failure and Renal Failure Gerasimos Filippatos, MD, FESC, FHFA President HFA Definition Epidemiology Pathophysiology Management (?) Recommendations for NHLBI in cardiorenal interactions related to
More informationOvercoming the Cardiorenal Syndrome
Overcoming the Cardiorenal Syndrome October 29, 2016 Randall C Starling MD MPH FACC FESC FHFSA FHFA Professor of Medicine Heart & Vascular Institute Cleveland Clinic Lerner College of Medicine Cleveland
More informationCardiorenal Syndrome: What the Clinician Needs to Know. William T. Abraham, MD Director, Division of Cardiovascular Medicine
Cardiorenal Syndrome: What the Clinician Needs to Know William T. Abraham, MD Director, Division of Cardiovascular Medicine Orlando, Florida October 7-9, 2011 Renal Hemodynamics in Heart Failure Glomerular
More informationMedical Management of Acutely Decompensated Heart Failure. William T. Abraham, MD Director, Division of Cardiovascular Medicine
Medical Management of Acutely Decompensated Heart Failure William T. Abraham, MD Director, Division of Cardiovascular Medicine Orlando, Florida October 7-9, 2011 Goals of Acute Heart Failure Therapy Alleviate
More informationThe Art and Science of Diuretic therapy
The Art and Science of Diuretic therapy Dr. Fayez EL Shaer Associate Professour of cardiology Consultant cardiologist MD, MSc, PhD, CBNC, NBE FESC, ACCP, FASNC,HFA KKUH, KFCC Heart failure: fluid overload
More informationKeynote Address II Managing Acute Heart Failure: What Can We Do to Improve Outcomes?
Keynote Address II Managing Acute Heart Failure: What Can We Do to Improve Outcomes? 24 th Annual San Diego Heart Failure Symposium June 1-2, 2018 La Jolla, CA Barry Greenberg, MD Distinguished Professor
More informationRecognizing and Treating Patients with the Cardio-Renal Syndrome
Recognizing and Treating Patients with the Cardio-Renal Syndrome Joachim H. Ix, MD, MAS, FASN Professor of Medicine Chief; Division of Nephrology-Hypertension University of California San Diego 1 Conflicts
More informationCardio-Renal Syndrome in Acute Heart Failure:
Cardio-Renal Syndrome in Acute Heart Failure: Target for Therapy Marvin A. Konstam, M.D. Research support and/or consulting relevant to this lecture: Merck, Otsuka, Johnson & Johnson; Amgen; Cardiokine
More informationManagement of Acute Heart Failure
Management of Acute Heart Failure Uri Elkayam, MD Professor of Medicine University of Southern California School of Medicine Los Angeles, California elkayam@usc.edu ADHF Treatments Goals.2 Improve symptoms.
More informationManagement of Advanced Systolic Heart Failure. Robert W. Hull MD FACC Associate Professor of Medicine West Virginia University
Management of Advanced Systolic Heart Failure Robert W. Hull MD FACC Associate Professor of Medicine West Virginia University American College of Cardiology Foundation (ACCF) American Heart Association
More informationHyponatremia in Heart Failure: why it is important and what should we do about it?
Objectives Hyponatremia in Heart Failure: why it is important and what should we do about it? Pathophysiology of sodium and water retention in heart failure Hyponatremia in heart failure (mechanism and
More informationJournal Watch. January. REVIEW: Diuretic Resistance in heart failure HEART FAILURE AND TRANSPLANTATION
Journal Watch January 2018 Lavanya Bellumkonda, MD, PhD Yale University School of Medicine New Haven, Connecticut, USA lavanya.bellumkonda@yale.edu Josephine Chou, MD Yale University School of Medicine
More informationMedical Management of Acute Heart Failure
Critical Care Medicine and Trauma Medical Management of Acute Heart Failure Mary O. Gray, MD, FAHA Associate Professor of Medicine University of California, San Francisco Staff Cardiologist and Training
More informationPearls in Acute Heart Failure Management
Pearls in Acute Heart Failure Management Best Practices Juan M. Aranda Jr., M.D. Professor of Medicine Medical Director of Heart Failure/ Transplant Program University of Florida College of Medicine Disclosures:
More informationSummary/Key Points Introduction
Summary/Key Points Introduction Scope of Heart Failure (HF) o 6.5 million Americans 20 years of age have HF o 960,000 new cases of HF diagnosed annually o 5-year survival rate for HF is ~50% Classification
More informationCardiorenal Syndrome Prof. Dr. Bülent ALTUN Hacettepe University Faculty of Medicine Department of Internal Medicine Division of Nephrology
Cardiorenal Syndrome Prof. Dr. Bülent ALTUN Hacettepe University Faculty of Medicine Department of Internal Medicine Division of Nephrology Heart and Kidney The kidney yin dominates water, The heart yang
More informationDefining and Managing the Cardiorenal Syndrome in Acute Decompensated Heart Failure. Barry M. Massie Professor of Medicine UCSF
Defining and Managing the Cardiorenal Syndrome in Acute Decompensated Heart Failure Barry M. Massie Professor of Medicine UCSF DISCLOSURES Consulting fees: Merck-Novacardia Novartis Bristol Myers Squibb
More informationTHE KIDNEY IN HYPOTENSIVE STATES. Benita S. Padilla, M.D.
THE KIDNEY IN HYPOTENSIVE STATES Benita S. Padilla, M.D. Objectives To discuss what happens when the kidney encounters low perfusion To discuss new developments and clinical application points in two scenarios
More informationPractical Points in Cardiorenal Syndrome
Practical Points in Cardiorenal Syndrome Vichai Senthong, MD. Cardiovascular Unit, Faculty of Medicine Khon Kaen university HFCT Annual Scientific Meeting June 16, 2017, Eastin Grand Sathorn Hotel, Bangkok
More informationAntialdosterone treatment in heart failure
Update on the Treatment of Chronic Heart Failure 2012 Antialdosterone treatment in heart failure 전남의대윤현주 Chronic Heart Failure Prognosis of Heart failure Cecil, Text book of Internal Medicine, 22 th edition
More informationCardiorenal syndrome. Sofie Gevaert. Ghent University Hospital, Belgium
Cardiorenal syndrome Sofie Gevaert Ghent University Hospital, Belgium Disclosures Consultancy Astra Zeneca Boegringer MSD Novartis 68 y old man, ADHF ICMP, ejection fraction 35 %: progressive dyspnea,
More informationNovel Approaches for Recognition and Management of Life Threatening Complications of AKI and CKD: Focus on Acute Cardiorenal Syndromes
Novel Approaches for Recognition and Management of Life Threatening Complications of AKI and CKD: Focus on Acute Cardiorenal Syndromes Peter A. McCullough, MD, MPH Baylor University Medical Center, Dallas
More informationMedical Treatment for acute Decompensated Heart Failure. Vlasis Ninios Cardiologist St. Luke s s Hospital Thessaloniki 2011
Medical Treatment for acute Decompensated Heart Failure Vlasis Ninios Cardiologist St. Luke s s Hospital Thessaloniki 2011 2010 HFSA guidelines for ADHF 2009 focused update of the 2005 American College
More informationCase Presentation. This presentation is the intellectual property of the author. Contact them for permission to reprint and/or distribute.
Worsening Renal Function in Heart Failure Patients Mark Drazner, MD, MSc Clinical Chief of Cardiology Medical Director, CHF/VAD/Transplant James M. Wooten Chair in Cardiology UT Southwestern Medical Center
More informationCardiorenal Syndrome
Cardiorenal Syndrome Peenida Skulratanasak, M.D. Division of Nephrology, Department of Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol University Definition of Cardiorenal syndrome (CRS) Structural
More informationUltrafiltration in Decompensated Heart Failure. Description
Subject: Ultrafiltration in Decompensated Heart Failure Page: 1 of 7 Last Review Status/Date: September 2016 Ultrafiltration in Decompensated Heart Failure Description Ultrafiltration is a technique being
More informationHeart Failure and Cardio-Renal Syndrome 1: Pathophysiology. Biomarkers of Renal Injury and Dysfunction
CRRT 2011 San Diego, CA 22-25 February 2011 Heart Failure and Cardio-Renal Syndrome 1: Pathophysiology Biomarkers of Renal Injury and Dysfunction Dinna Cruz, M.D., M.P.H. Department of Nephrology San Bortolo
More informationState of the Art: acute heart failure Is it just congestion?
ESC CONGRESS 2017 Barcelona, 26. 30. August 2017 State of the Art: acute heart failure Is it just congestion? S.B. Felix, FESC Klinik für Innere Medizin B Ernst-Moritz-Arndt-Universität Greifswald 1456
More informationState-of-the-Art: Treatment of Renal Dysfunction in Heart Failure. W. H. Wilson Tang, MD Cleveland Clinic, U.S.A.
State-of-the-Art: Treatment of Renal Dysfunction in Heart Failure W. H. Wilson Tang, MD Cleveland Clinic, U.S.A. Heart Failure Exacerbates Renal Insufficiency ADHERE Registry: Prevalence of CKD by egfr
More informationHeart failure: what should be changed? Prof. Gerasimos Filippatos Attikon University Hospital
Heart failure: what should be changed? Prof. Gerasimos Filippatos Attikon University Hospital Disclosures Chair or Committee Member of trials or registries sponsored by Novartis, Bayer, Cardiorentis, Servier
More informationIntravenous Inotropic Support an Overview
Intravenous Inotropic Support an Overview Shaul Atar, MD Western Galilee Medical Center, Nahariya Affiliated with the Faculty of Medicine of the Galilee, Safed, Israel INOTROPES in Acute HF (not vasopressors)
More informationVolume Control in. Wafaa El Aroussy,MD Prof of Cardiology Kasr El Aini Faculty of Medicine September 29 th, 2011
Volume Control in Heart Failure Wafaa El Aroussy,MD Prof of Cardiology Kasr El Aini Faculty of Medicine September 29 th, 2011 What is Heart Failure Heart failure is a multisystem disorder which is characterised
More informationROSE-AHF and Beyond. Gerasimos Filippatos, FESC, FHFA President Heart Failure Association
ROSE-AHF and Beyond Gerasimos Filippatos, FESC, FHFA President Heart Failure Association From: Braunwald s Heart Disease. 9th ed. Philadelphia, Elsevier, 2011 Determinants and forms of worsening renal
More informationCardiorenal and Renocardiac Syndrome
And Renocardiac Syndrome A Vicious Cycle Cardiorenal and Renocardiac Syndrome Type 1 (acute) Acute HF results in acute kidney injury Type 2 Chronic cardiac dysfunction (eg, chronic HF) causes progressive
More informationFluid Resuscitation in Critically Ill Patients with Acute Kidney Injury (AKI)
Fluid Resuscitation in Critically Ill Patients with Acute Kidney Injury (AKI) Robert W. Schrier, MD University of Colorado School of Medicine Denver, Colorado USA Prevalence of acute renal failure in Intensive
More informationDr.Nahid Osman Ahmed 1
1 ILOS By the end of the lecture you should be able to Identify : Functions of the kidney and nephrons Signs and symptoms of AKI Risk factors to AKI Treatment alternatives 2 Acute kidney injury (AKI),
More informationBiomarkers, the Kidney and the Heart: Acute Kidney Injury
Biomarkers, the Kidney and the Heart: Acute Kidney Injury 12th Annual Conference on Biomarkers in Heart Failure and Acute Coronary Syndromes: Diagnosis, Treatment and Devices San Diego May 13, 2016 Ravindra
More informationG. Allen Bryant III, M.D.,F.A.S.N Director Medical Subspecialties LMH Co-Director Renal Services LMH LMPC Chairman of Board
G. Allen Bryant III, M.D.,F.A.S.N Director Medical Subspecialties LMH Co-Director Renal Services LMH LMPC Chairman of Board Presentation Outline/Goals Convince you that having combined LV dysfunction and
More informationUpdate on Cardiorenal Syndrome: A Clinical Conundrum
Advances in Peritoneal Dialysis, Vol. 27, 2011 Eric J. Chan, 1 Kevin C. Dellsperger 1 3 Update on Cardiorenal Syndrome: A Clinical Conundrum Our understanding of the cardiorenal syndrome continues to progress.
More informationHeart Failure (HF) Treatment
Heart Failure (HF) Treatment Heart Failure (HF) Complex, progressive disorder. The heart is unable to pump sufficient blood to meet the needs of the body. Its cardinal symptoms are dyspnea, fatigue, and
More informationUltrafiltration in Decompensated Heart Failure. Description
Subject: Ultrafiltration in Decompensated Heart Failure Page: 1 of 9 Last Review Status/Date: September 2014 Ultrafiltration in Decompensated Heart Failure Description Ultrafiltration is a technique being
More informationDisclosures. Overview. Goal statement. Advances in Chronic Heart Failure Management 5/22/17
Disclosures Advances in Chronic Heart Failure Management I have nothing to disclose Van N Selby, MD UCSF Advanced Heart Failure Program May 22, 2017 Goal statement To review recently-approved therapies
More informationHeart Failure with Reduced EF. Dino Recchia, MD, FACC, FHFSA
Heart Failure with Reduced EF Dino Recchia, MD, FACC, FHFSA Heart Failure HF is the end phenotype of almost all CV disorders Complex clinical syndrome resulting from any structural or functional impairment
More informationHeart Failure Management Policy and Procedure Phase 1
1301 Punchbowl Street, Harkness Suite 225 Honolulu, Hawaii 96813 Phone (808) 691-7220 Fax: (808) 691-4099 www.queenscipn.org Policy and Procedure Phase 1 Policy Number: Effective Date: Revised: Approved
More informationMEDICAL MANAGEMENT OF PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION
MEDICAL MANAGEMENT OF PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION FRANCIS X. CELIS, D.O. OPSO FALL CONFERENCE PORTLAND, OR 16 SEPTEMBER 2017 OVERVIEW What are the ACC/AHA Stages of HF? What
More informationUltrafiltration in Decompensated Heart Failure. Description
Subject: Ultrafiltration in Decompensated Heart Failure Page: 1 of 9 Last Review Status/Date: September 2015 Ultrafiltration in Decompensated Heart Failure Description Ultrafiltration is a technique being
More informationChapter 21. Diuretic Agents. Mosby items and derived items 2008, 2002 by Mosby, Inc., an affiliate of Elsevier Inc.
Chapter 21 Diuretic Agents Renal Structure and Function Kidneys at level of umbilicus Each weighs 160 to 175 g and is 10 to 12 cm long Most blood flow per gram of weight in body 22% of cardiac output (CO)
More informationEstimated 5.7 million Americans with HF. 915, 000 new HF cases annually, HF incidence approaches
Heart Failure: Management of a Chronic Disease Jenny Bauerly RN, CHFN, APRN-BC Heart Failure (HF) Definition A complex clinical syndrome that can result from any structural or functional cardiac disorder
More informationCardio-renal syndrome.
Review Article Cardio-renal syndrome. http://www.alliedacademies.org/archives-of-general-internal-medicine/ ISSN: 2591-7951 Dhiraj Kumar*, Abhijeet Yelale, Girish Sabnis, Hetan Shah, Charan Lanjewar, Prafulla
More informationDisclosures. Advances in Chronic Heart Failure Management 6/12/2017. Van N Selby, MD UCSF Advanced Heart Failure Program June 19, 2017
Advances in Chronic Heart Failure Management Van N Selby, MD UCSF Advanced Heart Failure Program June 19, 2017 I have nothing to disclose Disclosures 1 Goal statement To review recently-approved therapies
More information2016 Update to Heart Failure Clinical Practice Guidelines
2016 Update to Heart Failure Clinical Practice Guidelines Mitchell T. Saltzberg, MD, FACC, FAHA, FHFSA Medical Director of Advanced Heart Failure Froedtert & Medical College of Wisconsin Stages, Phenotypes
More informationACUTE HEART FAILURE. Julie Gorchynski MD, MSc, FACEP, FAAEM. Department of Emergency Medicine Emergency Residency Program UTHSC, San Antonio TCEP 2014
ACUTE HEART FAILURE Julie Gorchynski MD, MSc, FACEP, FAAEM Department of Emergency Medicine Emergency Residency Program UTHSC, San Antonio TCEP 2014 No disclosures Objectives Overview Cases Current Therapy
More informationWhat s new in heart failure management? Yonsei Cardiovascular Center Yonsei University College of Medicine
What s new in heart failure management? Yonsei Cardiovascular Center Yonsei University College of Medicine Current Guideline of Treatment Asymptomatic Mild/Mod Severe Refractory Correct Cause: Arrhythmias
More informationHEART FAILURE. Heart Failure in the US. Heart Failure (HF) 3/2/2014
HEART FAILURE Martina Frost, PA-C Desert Cardiology of Tucson Northwest Medical Center March 2014 Heart Failure in the US Prevalence - ~5 million 650,000 new cases annually 300,000 deaths annually Leading
More informationHeart Failure: Guideline-Directed Management and Therapy
Heart Failure: Guideline-Directed Management and Therapy Guideline-Directed Management and Therapy (GDMT) was developed by the American College of Cardiology and American Heart Association to define the
More informationCardiorenal Syndrome
SOCIEDAD ARGENTINA DE CARDIOLOGIA Cardiorenal Syndrome Joint session ESC-SAC ESC Congress 2012, Munich César A. Belziti Hospital Italiano de Buenos Aires I have no conflicts of interest to declare Cardiorenal
More informationMedical Policy An Independent Licensee of the Blue Cross and Blue Shield Association
Ultrafiltration in Decompensated Heart Failure Page 1 of 9 Medical Policy An Independent Licensee of the Blue Cross and Blue Shield Association Title: Ultrafiltration in Decompensated Heart Failure Professional
More informationClinical Policy: Ultrafiltration for Heart Failure Reference Number: CP.MP.456
Clinical Policy: Reference Number: CP.MP.456 Effective Date: 11/16 Last Review Date: 11/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory and
More informationThe Failing Heart in Primary Care
The Failing Heart in Primary Care Hamid Ikram How fares the Heart Failure Epidemic? 4357 patients, 57% women, mean age 74 years HFSA 2010 Practice Guideline (3.1) Heart Failure Prevention A careful and
More informationContrast Induced Nephropathy
Contrast Induced Nephropathy O CIAKI refers to an abrupt deterioration in renal function associated with the administration of iodinated contrast media O CIAKI is characterized by an acute (within 48 hours)
More informationCLINICAL PRACTICE GUIDELINE
CLINICAL PRACTICE GUIDELINE Procedure: Congestive Heart Failure Guideline Review Cycle: Biennial Reviewed By: Amish Purohit, MD, MHA, CPE, FACHE Review Date: November 2014 Committee Approval Date: 11/12/2014
More informationSection 12: Evaluation and Management of Patients With Acute Decompensated Heart Failure
Journal of Cardiac Failure Vol. 12 No. 1 2006 Section 12: Evaluation and Management of Patients With Acute Decompensated Heart Failure Overview Acute decompensated heart failure (ADHF) has emerged as a
More informationHeart Failure Guidelines For your Daily Practice
Heart Failure Guidelines For your Daily Practice Juan M. Aranda, Jr., MD, FACC, FHFSA Professor of Medicine Director of Heart Failure and Cardiac Transplantation University of Florida College of Medicine
More informationThe Triple Threat. Cardiac Care in the NT Annual Workshop 2017 is proudly supported by:
The Triple Threat DR KELUM PRIYADARSHANA FRACP CONSULTANT NEPHROLOGIST ROYAL DARWIN HOSPITAL Cardiac Care in the NT Annual Workshop 2017 is proudly supported by: Pathogenesis Diabetes CKD CVD Diabetic
More informationHeart-failure or Kidney Failure?
Heart-failure or Kidney Failure? Dr Ajith James Consultant Nephrologist Barts Health and BHRUT Mr AR 65 yrs Case Type 2 DM, IHD-MI 1998, 2003. PCI x 3. CABG 2008, HT CCF with LVEF 30% 2014. NYHA Class
More informationImplementing the CardioMEMS HF System into the Management of Heart Failure Patients
Implementing the CardioMEMS HF System into the Management of Heart Failure Patients Robert W. Hull MD FACC Associate Professor of Medicine WVU Heart Institute Co-director, Arrhythmia Service Director,
More informationHeart failure. Failure? blood supply insufficient for body needs. CHF = congestive heart failure. increased blood volume, interstitial fluid
Failure? blood supply insufficient for body needs CHF = congestive heart failure increased blood volume, interstitial fluid Underlying causes/risk factors Ischemic heart disease (CAD) 70% hypertension
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Ultrafiltration in Heart Failure Page 1 of 8 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Ultrafiltration in Heart Failure Professional Institutional Original
More informationUniversity of Groningen. Diuretic response and renal function in heart failure ter Maaten, Jozine Magdalena
University of Groningen Diuretic response and renal function in heart failure ter Maaten, Jozine Magdalena IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish
More informationReview Article Therapeutic Options for the Management of the Cardiorenal Syndrome
SAGE-Hindawi Access to Research International Journal of Nephrology Volume 2011, Article ID 194910, 10 pages doi:10.4061/2011/194910 Review Article Therapeutic Options for the Management of the Cardiorenal
More informationDefinition of Congestive Heart Failure
Heart Failure Definition of Congestive Heart Failure A clinical syndrome of signs & symptoms resulting from the heart s inability to supply adequate tissue perfusion. CHF Epidemiology Affects 4.7 million
More informationHeart Failure. Subjective SOB (shortness of breath) Peripheral edema. Orthopnea (2-3 pillows) PND (paroxysmal nocturnal dyspnea)
Pharmacology I. Definitions A. Heart Failure (HF) Heart Failure Ezra Levy, Pharm.D. HF Results when one or both ventricles are unable to pump sufficient blood to meet the body s needs There are 2 types
More informationAkash Ghai MD, FACC February 27, No Disclosures
Akash Ghai MD, FACC February 27, 2015 No Disclosures Epidemiology Lifetime risk is > 20% for American s older than 40 years old. > 650,000 new cases diagnosed each year. Incidence increases with age: 2%
More information1/4/18. Heart Failure Guideline Review and Update. Disclosure. Pharmacist Objectives. Pharmacy Technician Objectives. What is Heart Failure?
Disclosure Heart Failure Guideline Review and Update I have had no financial relationship over the past 12 months with any commercial sponsor with a vested interest in this presentation. Natalie Beiter,
More informationThey may forget your name, but they will never forget how you made them feel.
Relax and Learn at the Farm 2013 Presented By DNP, RN, CCNS, CCRN-CMC, CHFN Cardiovascular Nursing Education Associations 1 They may forget your name, but they will never forget how you made them feel.
More informationCardio Renal Disease. Dr. Rajasekara Chakravarthi Head, Dept of Nephrology CARE Hospitals Hyderabad
Cardio Renal Disease Dr. Rajasekara Chakravarthi Head, Dept of Nephrology CARE Hospitals Hyderabad PREVALENCE OF CVD IS HIGH CAD LVH CHF (CLINICAL) (ECHO) (CLINICAL) GENERAL POPULATION 5-12% 20% 5% CKD
More informationClinical efficacy of ultrafiltration in the treatment of acute decompensated heart failure with diuretic resistance.
Biomedical Research 2017; 28 (14): 6155-6159 ISSN 0970-938X www.biomedres.info Clinical efficacy of ultrafiltration in the of acute decompensated heart failure with diuretic resistance. Jian Zhang, Qi
More informationManagement of acute decompensated heart failure and cardiogenic shock. Arintaya Phrommintikul Department of Medicine CMU
Management of acute decompensated heart failure and cardiogenic shock Arintaya Phrommintikul Department of Medicine CMU Acute heart failure: spectrum Case 64 y/o M with Hx of non-ischemic DCM (LVEF=25-30%)
More informationRenal Optimization Strategies Evaluation in Acute Heart Failure (ROSE AHF): A Randomized Clinical Trial
Renal Optimization Strategies Evaluation in Acute Heart Failure (ROSE AHF): A Randomized Clinical Trial Horng H Chen MD on behalf of the NHLBI Heart Failure Clinical Research Network Background AHF + Renal
More informationTips & tricks on how to treat an acute heart failure patient with low cardiac output and diuretic resistance
Tips & tricks on how to treat an acute heart failure patient with low cardiac output and diuretic resistance J. Parissis Attikon University Hospital, Athens, Greece Disclosures ALARM investigator received
More informationObjectives. Systolic Heart Failure: Definitions. Heart Failure: Historical Perspective 2/7/2009
Objectives Diastolic Heart Failure and Indications for Echocardiography in the Asian Population Damon M. Kwan, MD UCSF Asian Heart & Vascular Symposium 02.07.09 Define diastolic heart failure and differentiate
More informationHeart Failure: Combination Treatment Strategies
Heart Failure: Combination Treatment Strategies M. McDonald MD, FRCP State of the Heart Symposium May 28, 2011 None Disclosures Case 69 F, prior MIs (LV ejection fraction 25%), HTN No demonstrable ischemia
More informationAdvanced Care for Decompensated Heart Failure
Advanced Care for Decompensated Heart Failure Sara Kalantari MD Assistant Professor of Medicine, University of Chicago Advanced Heart Failure, Mechanical Circulatory Support and Cardiac Transplantation
More informationBiomarkers for optimal management of heart failure. Cardiorenal syndrome. Veli-Pekka Harjola Helsinki University Central Hospital Helsinki, Finland
Biomarkers for optimal management of heart failure Cardiorenal syndrome Veli-Pekka Harjola Helsinki University Central Hospital Helsinki, Finland Presenter Disclosure Information V-P Harjola The following
More informationSlide 1. Slide 2. Slide 3. Managing Acute Heart Failure Trials and Tribulations. Declaration of
Slide 1 Managing Acute Heart Failure Trials and Tribulations Martin R Cowie MD MSc FRCP FRCP (Ed) FESC Professor of Cardiology, Imperial College London m.cowie@imperial.ac.uk @ProfMartinCowie Slide 2 Declaration
More informationCongestive Heart Failure: Outpatient Management
The Chattanooga Heart Institute Cardiovascular Symposium Congestive Heart Failure: Outpatient Management E. Philip Lehman MD, MPP Disclosure No financial disclosures. Objectives Evidence-based therapy
More informationWORSENING OF RENAL FUNCTION AFTER RAS INHIBITION IN DECOMPENSATED HEART FAILURE: CLINICAL IMPLICATIONS
WORSENING OF RENAL FUNCTION AFTER RAS INHIBITION IN DECOMPENSATED HEART FAILURE: CLINICAL IMPLICATIONS George Bakris, MD, FASH, FAHA, FASN Professor of Medicine Director, Comprehensive Hypertension Center
More informationIntegrating Current Knowledge into Consensus Guidelines for Acute Decompensated Heart Failure
Integrating Current Knowledge into Consensus Guidelines for Acute Decompensated Heart Failure J. Herbert Patterson, Pharm.D., FCCP One of Four Continuing Education Programs in the Series, Acute Decompensated
More informationDISCLOSURES ACHIEVING SUCCESS THROUGH FAILURE: UPDATE ON HEART FAILURE WITH PRESERVED EJECTION FRACTION NONE
ACHIEVING SUCCESS THROUGH FAILURE: UPDATE ON HEART FAILURE WITH PRESERVED EJECTION FRACTION Lori M. Tam, MD Providence Heart Institute DISCLOSURES NONE 1 OUTLINE Systolic vs. Diastolic Heart Failure New
More informationRecently, much effort has been put into research. Advances in... Congestive Heart Failure Care. How is CHF diagnosed? 2.
Advances in... Congestive Heart Failure Care Heart failure can currently be considered an epidemic. The article discusses some of the recent advances in outpatient management of congestive heart failure.
More informationDIAGNOSIS AND MANAGEMENT OF DIURETIC RESISTANCE. Jules B. Puschett, M.D.
DIAGNOSIS AND MANAGEMENT OF DIURETIC RESISTANCE Jules B. Puschett, M.D. Diuretic Resistance A clinical circumstance in which patients do not respond to a combination of salt restriction and even large
More informationHyponatremia as a Cardiovascular Biomarker
Hyponatremia as a Cardiovascular Biomarker Uri Elkayam, MD Professor of Medicine University of Southern California Keck School of Medicine elkayam@usc.edu Disclosure Research grant from Otsuka for the
More informationNesiritide: Harmful or Harmless?
Nesiritide: Harmful or Harmless? Michael P. Dorsch, Pharm.D., and Jo Ellen Rodgers, Pharm.D. Nesiritide is the recombinant form of human B-type (brain) natriuretic peptide (BNP), and its amino acid sequence
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Proposed Health Technology Appraisal. Serelaxin for treating acute decompensation of heart failure
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Proposed Health Technology Appraisal Serelaxin for treating acute decompensation of heart Draft scope (pre-referral) Draft remit/appraisal objective To
More information2/3/2017. Objectives. Effective Heart Failure Management through Evidence Based Practice and Innovation
Effective Heart Failure Management through Evidence Based Practice and Innovation Jennifer Bauerly RN, CHFN, APRN-BC CentraCare Heart and Vascular Center Objectives Describe the scope and impact of heart
More informationImproving Transition of Care in Congestive Heart Failure. Mark J. Gloth, DO, MBA. Vice President, Chief Medical Officer HCR ManorCare
Improving Transition of Care in Congestive Heart Failure Mark J. Gloth, DO, MBA. Vice President, Chief Medical Officer HCR ManorCare Heart Failure Fastest growing clinical cardiac disease in the United
More informationDIAGNOSIS AND MANAGEMENT OF ACUTE HEART FAILURE
DIAGNOSIS AND MANAGEMENT OF ACUTE HEART FAILURE Mefri Yanni, MD Bagian Kardiologi dan Kedokteran Vaskular RS.DR.M.Djamil Padang The 3rd Symcard Padang, Mei 2013 Outline Diagnosis Diagnosis Treatment options
More information